You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of VPL Vaccine for RSV
SBC: SIGMOVIR BIOSYSTEMS, INC. Topic: NIAIDProject Summary Human respiratory syncytial virus (RSV) is recognized as the single most important viral cause of acute respiratory disease in infants and young children worldwide. Elderly populations and immunocompromised individuals are also at significant risk for serious RSV disease. Despite this very substantial disease burden imposed by RSV worldwide, there are no vaccines available. Severa ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Novel Small Molecule Therapeutics for Pancreatic Cancer
SBC: ChemRegen Inc Topic: NCIProject Summary/Abstract Developing new ways to treat pancreatic cancer is a significant challenge. Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States and results in an estimated 37,000 deaths/year. Pancreatic cancer therapeutic options are limited to surgery and/or combinations of chemotherapy and radiation. Unfortunately, late-stage diagnosis of pancreat ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
ChemoFilter: A Novel Catheter Device to Enable High-Dose Chemotherapy Treatment
SBC: CHEMOFILTER, INC. Topic: NCIProject Summary: Intravenous dosing of drugs for applications ranging from cancer chemotherapy to anti-microbials to lytic (blood clot dissolving) agents is limited by systemic toxicity. Currently, the only ways to remove drugs from the blood are throughnatural metabolism or costly impractical measures such as dialysis. Despite intense focus on targeted drug delivery agents, these therapies are c ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Developing Novel Therapies for Treating Breast-Cancer-Related Lymphedema
SBC: ADEPTHERA, LLC Topic: NCIDESCRIPTION (provided by applicant): Destruction of lymphatic vessels during the treatment of breast cancer by surgery and/or radiation therapy can lead to the development of secondary lymphedema. The breast-cancer-related lymphedema is associated with debilitating limb swelling, chronic inflammation, tissue fibrosis, and increased susceptibility to infection. It has been estimated that approximat ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Intra-procedure Deformable Ultrasound-MRI Fusion for Prostate Biopsies
SBC: ZMK Medical Technologies, Inc. Topic: NCIThis proposal is a collaborative effort between Yale University and the medical device company Eigen to develop a more robust and accurate method for the deformable fusion of pre-operative magnetic resonance images (MRI) and intra-procedure trans-rectal ultrasound (TRUS) images to guide prostate biopsy. Prostate cancer is a major cause of death in the U.S. and biopsy is the gold-standard for its d ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Validation of a Novel Treatment for Glioblastoma
SBC: CURTANA PHARMACEUTICALS INC Topic: NCI? DESCRIPTION (provided by applicant): The goal of this application is to study in vivo efficacy of CT102, a newly discovered inhibitor of the OLIG2 transcription factor in animal models of glioblastoma (GBM), a highly underserved area of pharmacotherapy. In this proposal, the experienced drug discovery group at Curtana Pharmaceuticals Inc. will conduct a pre-clinical evaluation of selectivity ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Targeting of Myc-Max dimerization for the treatment of cancer
SBC: SORRENTO THERAPEUTICS, INC. Topic: NCIDESCRIPTION (provided by applicant): Myc is a key transcriptional regulator due to its critical role in many fundamental cellular processes, such as cell cycle progression and cell growth. Therefore, dysregulation of Myc expression can lead to disease, including cancer. Myc is overexpressed in many human tumors, and it is estimated that 1 in 7 cancer deaths in the United States are resultant of hi ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics
SBC: PPI PHARMACEUTICALS, LLC Topic: NCIDESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Identification and Quantification of Sequence Specific RNA Modifications via the Alpha-Hemolysin Latch Zone
SBC: ELECTRONIC BIOSCIENCES, INC. Topic: NIDADESCRIPTION (provided by applicant): During this STTR program, Electronic BioSciences (EBS) proposes to develop a nanopore based system around our University of Utah collaborators newly developed technology that will be capable of identifying and quantifying sequence specific RNA modifications. A system capable of quantitative, low cost, high throughput, RNA modification characterization has the c ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Developing a Nrf2 activator for the treatment of scleroderma
SBC: CUREVEDA, LLC Topic: NIAMSDESCRIPTION (provided by applicant): Scleroderma is a devastating autoimmune disease with a chronic course, involving the overproduction of collagen leading to fibrosis of the skin and connective tissues. The disease has a range of symptoms including pain,stiffness and swelling of the joints, shortness of breath and gastrointestinal complications. More than 50% of patients with the aggressive form ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health